Nana Wu
The AmCham Taiwan Pharmaceutical Committee has issued a comprehensive set of policy recommendations aimed at bolstering Taiwan’s pharmaceutical supply resilience, ensuring the long-term sustainability of the National Health Insurance (NHI) system, and elevating the nation’s standing in the global healthcare market. At a time when global geopolitical shifts and economic volatility are reshaping international drug pricing and launch strategies, the Committee’s latest position paper emphasizes that Taiwan must modernize its regulatory and pricing frameworks to remain a priority destination for innovative therapies. The recommendations come as the administration of President Lai Ching-te advances its "Healthy Taiwan" vision, a multi-year initiative designed to improve public health outcomes and foster the growth of the biotechnology sector as a pillar of national security and economic strength.
A Strategic Pivot Toward Formalized U.S.-Taiwan Cooperation
Central to the Committee’s proposal is the establishment of a regularized, institutionalized policy dialogue mechanism between the United States and Taiwan. While recent years have seen significant breakthroughs in bilateral trade—most notably the duty-free treatment granted in the U.S. market for Taiwanese generic drugs and active pharmaceutical ingredients (APIs)—stakeholders argue that a more structured platform is necessary to navigate the complexities of the modern pharmaceutical landscape. The Committee urges the creation of a formal U.S.-Taiwan pharmaceutical policy dialogue that would bring together government officials, manufacturers, scholars, and healthcare experts to address regulatory alignment, pricing developments, and the introduction of breakthrough medicines.
To support this dialogue, the Committee suggests that the National Health Insurance Administration (NHIA) conduct biannual consultations with industry leaders. These sessions would serve as a critical feedback loop, allowing the government to review international economic trends and adjust domestic policies in real-time. Furthermore, the Committee proposes leveraging the existing Global Cooperation and Training Framework (GCTF) to showcase Taiwan’s healthcare governance on the world stage. By sharing its expertise in NHI management and pandemic preparedness with global partners, Taiwan can reinforce its reputation as a "trusted partner" in the global supply chain, aligning with the "Five Trusted Industries" initiative championed by the current administration.
Aligning Reimbursement with Global Clinical Standards
A significant portion of the Committee’s report focuses on the "Healthy Taiwan" policy, particularly its focus on cancer care. The government’s pledge to align cancer drug reimbursement with international treatment guidelines has been met with praise; however, the Committee notes that substantial gaps persist in other therapeutic areas. Currently, many non-cancer medicines and certain advanced oncology treatments in Taiwan are subject to restrictive reimbursement conditions that do not match global standards. These restrictions often manifest as limitations on eligible patient populations, requirements for multiple prior lines of treatment, or caps on dosing and duration.
Such misalignments have a dual negative impact. First, they prevent Taiwanese physicians from providing the highest standard of care as recognized by international medical societies. Second, they hinder Taiwan’s ability to participate in international clinical trials. When local reimbursement criteria are out of sync with global protocols, it becomes difficult for researchers to accumulate the clinical data necessary for international collaboration. To rectify this, the Committee recommends an accelerated effort to align reimbursement conditions across all disease areas with international guidelines, thereby enhancing the global clinical value of Taiwan’s healthcare system and ensuring that patients have timely access to life-saving innovations.
Funding Innovation and Enhancing System Resilience
The financial sustainability of the NHI remains a core concern for both the government and the private sector. The Committee welcomed the announcement of a dedicated Cancer Drugs Fund, which is expected to reach approximately NT$10 billion (US$310 million) by 2025. However, the report argues that for such funding to be effective, the NHI must move away from short-term financial controls and adopt a medium- to long-term budgeting outlook. This approach would utilize "horizon scanning"—an early-warning system that analyzes upcoming medical technologies and pharmaceutical trends—to anticipate future expenditures and allocate resources more precisely.
Moreover, the Committee emphasized that a stable regulatory environment is essential for attracting multinational pharmaceutical companies to invest in R&D within Taiwan. The report highlights the importance of maintaining and strengthening incentive mechanisms, such as pricing premiums for drugs that undergo domestic clinical trials. By rewarding companies that contribute to Taiwan’s local research ecosystem, the government can ensure that patients benefit from globally innovative therapies earlier while simultaneously building the nation’s internal healthcare capacity.
Modernizing Drug Pricing and Market Access
The global pharmaceutical market is currently undergoing a period of intense scrutiny regarding pricing structures. As headquarters of multinational corporations review their global launch strategies, Taiwan’s pricing framework must remain competitive to avoid being deprioritized. The Committee recommends that the NHI Pharmaceutical Reimbursement and Payment Standards be updated to reflect the median price of 10 reference countries. Additionally, value-based adjustments should be introduced to account for clinical effectiveness, safety, convenience, and specific needs such as pediatric use.
A particular point of contention addressed in the report is the use of pharmaceutical reimbursement agreements (PRAs). While these agreements are intended to accelerate access to new drugs while managing budget impacts, the Committee notes that current implementations often prioritize high rebate requirements and hard spending caps. In an era of "international reference pricing," where the price set in one market can trigger price drops in others, excessively compressed prices in Taiwan may lead companies to delay or bypass the Taiwanese market entirely. The Committee calls for a framework based on procedural fairness, reasonable risk-sharing, and strict confidentiality to ensure that Taiwan remains an attractive market for the world’s most advanced medicines.
Lifecycle Management and the Drug Expenditure Target (DET)
To ensure a resilient drug supply, the Committee argues for a holistic "lifecycle management" approach to pharmaceutical pricing. A major hurdle identified is the Drug Expenditure Target (DET) system, a pilot budget control mechanism that has been in place for over a decade. The Committee points out that the baseline value used for DET calculations has not been updated in more than ten years, failing to reflect actual drug expenditures. This stagnation results in distorted pricing signals that can undermine supply stability and discourage the entry of new products.
Furthermore, the report raises concerns about the protection of intellectual property (IP). Currently, price protection is often limited to drugs with primary active-ingredient patents, leaving innovative medicines with valid secondary patents vulnerable to price reductions under "patent expiry" rules. This practice, according to the Committee, is inconsistent with international patent norms and diminishes the lifecycle value of innovation. By recalibrating the DET baseline and expanding patent-related price protections, Taiwan can foster a more predictable investment environment that respects the high costs associated with pharmaceutical R&D.
Proactive Risk Management and the Pharmaceutical Affairs Act
The recent amendment to Article 27 of the Pharmaceutical Affairs Act represents a significant step toward proactive drug shortage management. The Committee commended the government for shifting from a reactive "ex-post facto" response to a "front-end" risk management strategy. However, the report cautions that the subordinate regulations currently under development must be carefully balanced to avoid imposing excessive administrative burdens on the industry.
The Committee recommends a risk-based approach to reporting and supply intervention. Products with a history of stable supply should not be subject to the same level of oversight as those at high risk of shortage. Additionally, the report stresses that forecast data provided by companies should be used exclusively for monitoring purposes and should not be used as a basis for punitive actions. Ongoing dialogue between the Ministry of Health and Welfare (MOHW) and industry stakeholders will be vital to ensuring that these regulations achieve their goal of supply resilience without stifling market efficiency.
Analysis: The Path Forward for Taiwan’s Healthcare Globalism
The recommendations put forth by the AmCham Taiwan Pharmaceutical Committee reflect a broader trend in global healthcare: the shift toward "health security" as a component of national security. For Taiwan, which faces unique geopolitical pressures, maintaining a robust and innovative pharmaceutical sector is not merely a matter of public health but a strategic necessity. The focus on aligning with international standards and formalizing U.S.-Taiwan ties suggests a desire to integrate Taiwan more deeply into the Western pharmaceutical supply chain.
However, the path to reform is fraught with fiscal challenges. The NHI system, while globally lauded for its universal coverage and efficiency, faces an aging population and rising costs for advanced therapies. Balancing the need for "fair R&D cost-sharing" with the government’s mandate to keep healthcare affordable will require delicate negotiation. The proposal for a NT$10 billion Cancer Drugs Fund is a start, but as the Committee notes, the underlying pricing mechanisms—such as the DET and rebate systems—require fundamental modernization to ensure that these funds actually translate into improved patient access.
Ultimately, the success of the "Healthy Taiwan" initiative will depend on whether the government can transform the NHI from a cost-containment system into an investment-driven ecosystem. By adopting the Committee’s suggestions for regularized dialogue, international alignment, and predictable lifecycle management, Taiwan has the opportunity to solidify its position as a premier pharmaceutical hub in the Asia-Pacific region, ensuring that its citizens continue to benefit from the vanguard of global medical innovation.
Layla Zulfa
Lina Irawan
